This site is intended for healthcare professionals only

Journal of
Diabetes Nursing

Issue:

Share this article

How does knowing an up-to-date HbA 1c affect decision making in the outpatient clinic?

John Clark
, Alistair Green

Having an up-to-date HbA1c during consultations in the outpatient clinic improves the effectiveness and efficiency of the clinic in the authors’ experience. This study examines the impact of having an up-to-date HbA1c on a person with diabetes’ management and treatment plans. Clinicians’ decision-making and the ramifications for the clinic and the multidisciplinary team are also reported.

Glycated haemoglobin (HbA1c) measurement has revolutionised the management of diabetes. It gives an accurate guide to the average glycaemia over the preceding 3 months and is now a standard measure of glycaemic control.

Studies have confirmed that the level of HbA1c is closely linked to the future development of diabetes-related complications and the risk of developing these complications is significantly reduced if HbA1c is less than 7.5% (Writing Team for the DCCT/Epidemiology of Diabetes Interventions and Complications Research Group, 2002; UK Prospective Diabetes Study Group, 1998; Diabetes Control and Complications Trial Research Group, 1995).

It is routine practice to measure HbA1c to determine a patient’s level of glycaemic control and QOF points are available for doing so. HbA1c measurements are generally performed in diabetes clinics in one of two ways: in the laboratory or as a near-patient test. Using the laboratory method, blood is taken from the patient before the clinic and sent to the laboratory – unless the patient has had their blood taken before the day of the appointment, the result will not be ready for the consultation.

Near-patient testing (NPT) leads to HbA1c results being available at the time of the consultation which is considered to be the main advantage of NPT over laboratory testing.

Grieve and colleagues (1999) conducted an extensive trial comparing laboratory HbA1c testing to NPT. This study showed that people with diabetes were more likely to have a change in management if the HbA1c was done as a near-patient test compared with laboratory testing. However, from the paper it is not clear what sort of management was changed; whether it was referrals to the DSN or insulin dose changes.

Several other studies compare laboratory-based HbA1c testing to NPT. These studies show that using NPT can help to achieve a small but significant decrease in HbA1c over time compared with using laboratory testing (Petersen et al, 2007; Miller et al, 2003; Ferenczi et al, 2001; Thaler et al, 1999).

The current study was designed to investigate any other advantages to the person with diabetes and clinical team by using NPT, specifically what changes in patient management may occur when the HbA1c result is directly available during the patient consultation.

Methods
Three-hundred and twenty-eight individuals were recruited consecutively from the diabetes clinic at West Suffolk Hospital between November 2003 and February 2004. Blood was taken for an HbA1c measurement using a DCA 2000 near-patient HbA1c tester (Bayer Diagnostics, Newbury) and the result placed in a sealed envelope. The patient was then seen by a member of the diabetes team and a management plan was formulated and documented on the research sheet as one or more of the following.

  • No change to current management.
  • Referral to dietitian.
  • Referral to DSN.
  • Change oral medication.
  • Change insulin dosage.
  • Initiate oral medication.
  • Initiate insulin.

In order to mimic the normal clinic as much as possible, the clinician would have the patient’s previous HbA1c results to hand, so only the measurement on the day of the clinic was blinded. The clinician would then open the envelope and discover the patient’s HbA1c. The clinician would then review their proposed management plan and change it if necessary in light of the now available HbA1c result. The change in management as a result of knowing the HbA1c could be one of the following.

  • A withheld management change. This occurred when the HbA1c is better than anticipated and the proposed management change is no longer deemed necessary.
  • An implemented management change. This occurred when during initial interview no change in the patient’s management was planned, but when an elevated HbA1c result became available a change in management was implemented.

The Suffolk local research and ethics committee approved the project. Statistical testing was not possible due to the design of the study.

Results
This study revealed 143 unanticipated changes in management made after the HbA1c result was known to the clinician (43.6%; Table 1).

The two major changes in management that occurred when the HbA1c result was known were related to DSN referral and changing insulin dosage (Table 2). Once the HbA1c result was known it was agreed by the clinician and patient to change the initial plan: 40 people were referred to a DSN because their HbA1c was higher than anticipated. However, a further 16 were no longer required to see a DSN because their HbA1c was better than anticipated. The availability of the HbA1c result enabled more appropriate referral of clinic patients to the DSN, particularly concentrating on those with higher than expected HbA1c measurements, thus cutting back on inappropriate referrals to this hard-pressed service.

Similarly, in 34 patients the clinician decided to make a change in insulin dosage once the HbA1c result was known and withdrew a planned change in insulin treatment in 12 patients when the result was better than expected. Thus, availability of the HbA1c value resulted in more appropriate insulin treatment for 46 patients, 12 of whom were being considered for insulin changes that they did not need.

The value of the HbA1c was so unexpected for a few individuals that once it was known, the management plan was overhauled completely and the patients were commenced on oral hypoglycaemic agents (n=4) or insulin (n=5).

Conclusions
This study demonstrates that if people with diabetes are seen in clinic with an up-to-date HbA1c result, then more appropriate management plans can be developed for each person. It appears that if management plans are drawn up without knowing current HbA1c result, around half of those with diabetes will require alterations to their plan once the result is available. As there may be a delay of several days or weeks in getting a laboratory HbA1c result linked to the patient’s record, it is possible that some of these required changes will never be carried through. Therefore having the HbA1c result instantly available ensures changes in management can be discussed and implemented there and then.

In addition, having the HbA1c result immediately allows more efficient and appropriate referral to other members of the multidisciplinary diabetes team, in particular to the DSN.

Having an instantly available HbA1c greatly influenced the decision to refer patients to the DSN and/or dietitian. This highlights the importance of the role of the DSN and the dietitian in improving patients’ HbA1c. The DSN and dietitian felt that this was appropriate provided it did not prevent patients with a lower HbA1c from seeing them if they wished to.

It should be highlighted that although HbA1c is an important outcome for glycaemic control in audit and research, it is not the only measure of glycaemic control. People with good glycaemic control have been shown to have undocumented hypo- and hyperglycaemia with continuous glucose monitoring systems (CGMS; Hay et al, 2003). Due to the limited availability of CGMS, home glucose monitoring is the principal method that allows detection of these glucose fluctuations and allows day-to-day changes in treatment in response to changes in lifestyle (Renard, 2005).

The usefulness of an individuals’ self-monitoring logbook depends upon their accuracy and, as accuracy can be variable, downloading blood glucose readings from the person with diabetes’ meter may be more reliable.

Over recent years NPT has become increasingly popular despite the evidence for its efficiency and cost-effectiveness being limited. It has been suggested that clinicians’ confidence in NPT’s advantages over laboratory testing that has driven its popularity (Grieve et al, 1999). The availability of a current HbA1c result at consultation is perceived as a real advantage as it indicates whether additional treatment is likely and allows patient involvement in treatment decisions and goal setting (Miller et al, 2003). Involving people with diabetes in their treatment decisions is thought to help their motivation and concordance (Greenfield et al, 1988). As near-patient HbA1c measurement is nearly as accurate and reliable as laboratory HbA1c measurement (Hawkins, 2003) additional cost is less of a barrier to their use.

In conclusion the authors feel that NPT for HbA1c is an important tool required for the effective running of an outpatient diabetes service.

REFERENCES:

Diabetes Control and Complications Trial Research Group (1995) The effect of intensive diabetes therapy on the development and progression of neuropathy. The Diabetes Control and Complications Trial Research Group. Annals of Internal Medicine 122: 561–8
Ferenczi A, Reddy K, Lorber DL (2001) Effect of immediate hemoglobin A1c results on treatment decisions in office practice. Endocrine Practice 7: 85–8
Greenfield S, Kaplan SH, Ware JE Jr et al (1988) Patients’ participation in medical care: effects on blood sugar control and quality of life in diabetes. Journal of General Internal Medicine 3: 448–57
Grieve R, Beech R, Vincent J, Mazurkiewicz J (1999) Near patient testing in diabetes clinics: appraising the costs and outcomes. Health Technology Assessment 3: 1–74
Hawkins RC (2003) Comparison of four point-of-care HbA1c analytical systems against central laboratory analysis. Singapore Medical Journal 44: 8–11
Hay LC, Wilmshurst EG, Fulcher G (2003) Unrecognized hypo- and hyperglycemia in well-controlled patients with type 2 diabetes mellitus: the results of continuous glucose monitoring. Diabetes Technology and Therapeutics 5: 19–26
Miller CD, Barnes CS, Phillips LS (2003) Rapid A1c availability improves clinical decision-making in an urban primary care clinic. Diabetes Care 26: 1158–63
Petersen JR, Finley JB, Okorodudu AO (2007) Effect of point-of-care on maintenance of glycemic control as measured by A1C. Diabetes Care 30: 713–5
Renard E (2005) Monitoring glycemic control: the importance of self-monitoring of blood glucose. American Journal of Medicine 118(Suppl 9A): 12S–19S
Thaler LM, Ziemer DC, Gallina DL (1999) Diabetes in urban African-Americans. XVII. Availability of rapid HbA1c measurements enhances clinical decision-making. Diabetes Care 22: 1415–21
UKPDS Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352: 837–53
Writing Team for the DCCT/Epidemiology of Diabetes Interventions and Complications Research Group (2002) Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. Journal of the American Medical Association 287: 2563–9

Related content
Latest news: New indication for semaglutide, and diabetes education for deaf communities
;
Free for all UK & Ireland healthcare professionals

Sign up to all DiabetesontheNet journals

 

By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.

We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.